<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584699</url>
  </required_header>
  <id_info>
    <org_study_id>33320140105</org_study_id>
    <nct_id>NCT02584699</nct_id>
  </id_info>
  <brief_title>Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC</brief_title>
  <official_title>Phase II Study of Stereotactic Ablative Radiotherapy in Elderly Patients With Stage I Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luhua Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to prospectively investigate the efficacy, toxicity and quality of life (QOF)
      of stereotactic ablative radiotherapy (SABR) using a moderate fractionation of 72 Gy/6 Gy/12
      F (BED10 = 115 Gy) in a single arm of elderly ( ≥ 70) patients with stage I (2009 UICC)
      non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to prospectively investigate the local regional control, overall survival,
      treatment related toxicities and quality of life (QOF) of elderly stage I NSCLC patients
      receiving stereotactic ablative radiotherapy (SABR) with a moderate fractionation of 72 Gy/6
      Gy/12 F (BED10 = 115 Gy). Patients' general characteristics, treatment modality, dose-volume
      histogram (DVH) parameters, toxicity profiling, quality of life, pattern of failure as well
      as survival time will be prospective recorded for the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local regional progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Duration between radiotherapy commencement and local progression, regional progression, death of cancer or last date of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 month after RT</time_frame>
    <description>Tumor response to radiotherapy evaluated by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Duration between radiotherapy commencement and any progression, death of cancer or last date of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>Duration between radiotherapy commencement and any cause of death or last date of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 2 radiation induced normal tissue toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of radiation induced toxicities on lung, oesophagus, rib or chest wall pain assessed by CTCAE v 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire on quality of life</measure>
    <time_frame>2 year</time_frame>
    <description>Physical and psychologic status assessed by specific questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy (SABR)</intervention_name>
    <description>Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy</description>
    <arm_group_label>SABR</arm_group_label>
    <other_name>Stereotactic body radiation therapy (SBRT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 70

          -  Pathologically or cytologically confirmed NSCLC

          -  Stage T1- 2 N0M0 based on adequate workup

          -  Peripheral tumor

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Inoperable NSCLC

        Exclusion Criteria:

          -  Pathologically or cytologically confirmed SCLC

          -  Direct evidence of regional or distant metastasis

          -  Central tumor

          -  Past history of malignancy

          -  Past history of thoracic irradiation

          -  Past history of chemotherapy

          -  Past history of thoracic surgery

          -  Pure Bronchioalveolar adenocarcinoma

          -  Active systemic, pulmonary or pleural lung diseases

          -  Pulmonary infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingbo Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital/Institute, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingbo Wang, Dr.</last_name>
    <phone>8610-87788503</phone>
    <email>wangjingbo303@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luhua Wang, Dr.</last_name>
    <phone>8610-87788799</phone>
    <email>wlhwq@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital/Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingbo Wang, Dr.</last_name>
      <phone>8610-87788503</phone>
      <email>wangjingbo303@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Luhua Wang, Dr.</last_name>
      <phone>8610-87788799</phone>
      <email>wlhwq@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jingbo Wang, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luhua Wang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhouguang Hui, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JianYang Wang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994 Oct 1;74(7 Suppl):2101-6.</citation>
    <PMID>8087777</PMID>
  </reference>
  <reference>
    <citation>Yang L, Li L, Chen Y, Parkin DM. [Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China]. Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):274-8. doi: 10.3779/j.issn.1009-3419.2005.04.05. Chinese.</citation>
    <PMID>21108881</PMID>
  </reference>
  <reference>
    <citation>Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, Thun MJ. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003 Jun 15;97(12 Suppl):3133-275. Erratum in: Cancer. 2005 Jun 15;103(12):2658.</citation>
    <PMID>12784323</PMID>
  </reference>
  <reference>
    <citation>Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007 Jul;132(1):193-9. Epub 2007 May 15.</citation>
    <PMID>17505036</PMID>
  </reference>
  <reference>
    <citation>Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001 Aug;56(8):628-38. Review.</citation>
    <PMID>11462066</PMID>
  </reference>
  <reference>
    <citation>Dosoretz DE, Galmarini D, Rubenstein JH, Katin MJ, Blitzer PH, Salenius SA, Dosani RA, Rashid M, Mestas G, Hannan SE, et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):507-16.</citation>
    <PMID>8226142</PMID>
  </reference>
  <reference>
    <citation>Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010 Mar 17;303(11):1070-6. doi: 10.1001/jama.2010.261.</citation>
    <PMID>20233825</PMID>
  </reference>
  <reference>
    <citation>Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012 Aug;13(8):802-9. doi: 10.1016/S1470-2045(12)70242-5. Epub 2012 Jun 22.</citation>
    <PMID>22727222</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Luhua Wang</investigator_full_name>
    <investigator_title>Deputy president, Cancer Hospital, Chinese Academy of Medical Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

